David Cooper

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses
    David Cooper
    Department of Vaccines Discovery Research, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Vaccine 23:236-46. 2004
  2. pmc Herpes simplex virus type 2 UL24 gene is a virulence determinant in murine and guinea pig disease models
    Susan Blakeney
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    J Virol 79:10498-506. 2005
  3. pmc Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge
    Robert J Natuk
    Department of Vaccines Discovery Research, Wyeth Research, 401 N Middletown Rd, Pearl River, New York 10965, USA
    J Virol 80:4447-57. 2006
  4. ncbi Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction
    David Cooper
    Department of Vaccines Discovery Research, Wyeth Research, Pearl River, NY 10965, USA
    Cell Immunol 239:113-20. 2006
  5. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
  6. pmc Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice
    David Cooper
    Wyeth, 401 N Middletown Rd, Pearl River, NY 10965, USA
    J Virol 82:207-19. 2008
  7. pmc Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations
    David K Clarke
    Wyeth Vaccines Discovery Research, 401 N Middletown Road, Bldg 180 267, Pearl River, NY 10965, USA
    J Virol 81:2056-64. 2007
  8. pmc In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation
    J Erik Johnson
    Wyeth Vaccines Research, Pearl River, NY 10965, USA
    Vaccine 27:2930-9. 2009
  9. ncbi Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector
    David K Clarke
    Department of Vaccines Discovery Research, Wyeth Research, Wyeth, Pearl River, NY 10965, USA
    Springer Semin Immunopathol 28:239-53. 2006
  10. pmc The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
    David Cooper
    Pfizer Vaccine Research, Pfizer, Pearl River, NY 10965, United States
    Vaccine 29:7207-11. 2011

Detail Information

Publications34

  1. ncbi Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses
    David Cooper
    Department of Vaccines Discovery Research, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Vaccine 23:236-46. 2004
    ..This acquired protection persisted up to 1 year. Finally, adsorbing gD and IL-12 to AlPO4 decreased the optimal dose of IL-12 required to enhance gD immunogenicity and shift responses towards a Th1-like profile...
  2. pmc Herpes simplex virus type 2 UL24 gene is a virulence determinant in murine and guinea pig disease models
    Susan Blakeney
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    J Virol 79:10498-506. 2005
    ..Although genital lesions developed in some UL24-betagluc-inoculated guinea pigs, both the overall number of lesions and the severity of disease were far less than that observed for animals infected with parental strain 186...
  3. pmc Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge
    Robert J Natuk
    Department of Vaccines Discovery Research, Wyeth Research, 401 N Middletown Rd, Pearl River, New York 10965, USA
    J Virol 80:4447-57. 2006
    ..In summary, rVSV-gD vectors were successfully used to elicit potent anti-gD Th1-like cellular and humoral immune responses that were protective against HSV-2 disease in guinea pigs and mice...
  4. ncbi Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction
    David Cooper
    Department of Vaccines Discovery Research, Wyeth Research, Pearl River, NY 10965, USA
    Cell Immunol 239:113-20. 2006
    ..The location of this novel epitope emphasizes the benefit of using full-length versions of glycoproteins when designing vaccine components...
  5. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  6. pmc Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice
    David Cooper
    Wyeth, 401 N Middletown Rd, Pearl River, NY 10965, USA
    J Virol 82:207-19. 2008
    ..These findings demonstrate that through directed manipulation of the rVSV genome, vectors that have reduced neurovirulence and enhanced immunogenicity can be made...
  7. pmc Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations
    David K Clarke
    Wyeth Vaccines Discovery Research, 401 N Middletown Road, Bldg 180 267, Pearl River, NY 10965, USA
    J Virol 81:2056-64. 2007
    ..The results show synergistic rather than cumulative increases in attenuation and demonstrate a new approach to the attenuation of VSV and possibly other viruses...
  8. pmc In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation
    J Erik Johnson
    Wyeth Vaccines Research, Pearl River, NY 10965, USA
    Vaccine 27:2930-9. 2009
    ..These studies demonstrated significant differences in the biodistribution patterns of and the associated pathogenicity engendered by the prototypic and attenuated vectors in a highly susceptible host...
  9. ncbi Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector
    David K Clarke
    Department of Vaccines Discovery Research, Wyeth Research, Wyeth, Pearl River, NY 10965, USA
    Springer Semin Immunopathol 28:239-53. 2006
    ..Additional modifications of further attenuated rVSV vectors to upregulate expression of HIV-1 antigens and coexpress molecular adjuvants are also being developed in an effort to balance immunogenicity and attenuation...
  10. pmc The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
    David Cooper
    Pfizer Vaccine Research, Pfizer, Pearl River, NY 10965, United States
    Vaccine 29:7207-11. 2011
    ..Taken together these results suggest that immunization with PCV13 has the potential to induce cross-protective responses to related serotypes not directly covered by the vaccine...
  11. ncbi 13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model
    Philip Fernsten
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:75-84. 2011
    ..These data suggest that PCV13 will provide protection against pneumococcal serotype 1, 3, and 5 disease in human populations, even at relatively low OPA titers...
  12. ncbi Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
    Bonaventura Clotet
    Hospital Universitari Germans Trias I Pujol and irsiCaixa Foundation, Ctra de Canyet s n 08916, Barcelona, Catalonia, Spain
    Lancet 369:1169-78. 2007
    ..We did a pooled subgroup analysis to update results at week 48 for patients receiving the recommended dose of darunavir-ritonavir compared with those receiving other protease inhibitors (PIs)...
  13. doi Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women
    Inmaculada Jarrin
    National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
    Am J Epidemiol 168:532-40. 2008
    ..74, 95% CI: 0.56, 0.98). Sex differences in HIV disease progression have become larger and statistically significant in the era of highly active antiretroviral therapy, supporting a stronger impact of health interventions among women...
  14. ncbi CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Lancet 368:459-65. 2006
    ..Stopping antiretroviral therapy in patients with HIV-1 infection can reduce costs and side-effects, but carries the risk of increased immune suppression and emergence of resistance...
  15. ncbi Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study
    Dominic E Dwyer
    Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia
    Antivir Ther 11:409-19. 2006
    ..6 kg). Baseline NRTI-associated toxicities resolved in 17% of participants during follow-up. Enfuvirtide is an important component of antiretroviral therapy in highly treatment-experienced individuals where NRTI sparing may be desirable...
  16. doi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  17. ncbi Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients
    Joseph C Gathe
    Therapeutic Concepts, 4900 Fannin Street, Houston, TX 77004, USA
    AIDS Res Hum Retroviruses 23:216-23. 2007
    ..The 500 mg/200 mg dose achieved the best efficacy, safety, and pharmacokinetic profile in this highly treatment-experienced population and was selected for the pivotal phase 3 studies...
  18. ncbi Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 40:413-21. 2005
    ..The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients...
  19. ncbi Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection
    Jan Andersson
    Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    J Infect Dis 185:1355-8. 2002
    ..This suggests that mechanisms inhibiting CTL-mediated cytotoxicity are operative in lymphoid tissue early in the course of HIV infection...
  20. ncbi Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study
    Martyn French
    Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, WA, Australia
    HIV Clin Trials 3:177-85. 2002
    ..To assess and compare the efficacy and safety of three triple combination antiretroviral therapies in HIV-1-infected treatment-naive patients...
  21. ncbi Significant differences between plasma HIV-1 RNA assays in HIV-1 subtype E infected patients treated with antiretroviral therapy
    Kiat Ruxrungtham
    The Netherlands, Australia Thailand Research Collaboration HIV NAT, Thai Red Cross AIDS Research Centre, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Asian Pac J Allergy Immunol 20:105-11. 2002
    ..As the current goal of therapy is to suppress plasma viral load below the detection limit of the assays, the significant differences between the assays may influence antiretroviral efficacy evaluation and management...
  22. ncbi Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks
    Abdel Babiker
    Int J Epidemiol 31:951-8. 2002
    ..We wished to evaluate changes over time in the risk of specific AIDS-defining diseases, as first events, using data from individuals with known dates of HIV seroconversion...
  23. ncbi Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individuals
    Alison Clegg
    Department of Immunology, Westmead Hospital, New South Wales 2145, Australia
    Clin Immunol 106:36-40. 2003
    ..03). This study highlights the importance of interactions between IL-2 and CCR5; at the clinical level, it argues for assessment of chemokine receptor genotype in IL-2 and perhaps other immune-based therapy trials...
  24. ncbi False negative HIV-1 proviral DNA polymerase chain reaction in a patient with primary infection acquired in Thailand
    Philip Cunningham
    NSW State Reference Laboratory for HIV AIDS, Centre for Immunology, St Vincent s Hospital, Sydney, NSW 2010, Australia
    J Clin Virol 26:163-9. 2003
    ....
  25. ncbi Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    Adriano Lazzarin
    Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Vita Salute University, Milan, Italy
    N Engl J Med 348:2186-95. 2003
    ....
  26. ncbi Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors
    Sunee Sirivichayakul
    Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    AIDS 17:1889-96. 2003
    ..To investigate genotypic drug resistance in HIV-1 subtype A/E infection associated with failure of double/triple-nucleoside reverse transcriptase (RT) inhibitor therapy...
  27. ncbi Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial
    Jintanat Ananworanich
    HIVNAT The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center
    AIDS 17:F33-7. 2003
    ..A schedule of 1 week on and 1 week off therapy offers the promise of 50% less drug exposure with continuously undetectable HIV RNA concentration...
  28. ncbi Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations
    Bonaventura Clotet
    Hospital Universitari Germans Trias i Pujol and the Institut de Recerca de la SIDA Caixa Foundation, Badalona, Barcelona, Spain
    AIDS 18:1137-46. 2004
    ..An initial investment in establishing such procedures can be expected to yield significant returns in patient confidence and benefit on enfuvirtide...
  29. ncbi Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment
    Reto Nuesch
    HIV Netherlands, Australia, Thailand Research Collaboration HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Clin Infect Dis 40:728-34. 2005
    ..One major concern, however, is the development of resistance to antiretroviral drugs that can occur during multiple cycles of starting and stopping therapy...
  30. ncbi Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine
    Ana Barrios
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 19:569-75. 2005
    ..The popularity of this combination, however, has been questioned due to concerns about pharmacokinetic interactions and increased risk of pancreatitis and hyperglycemia. Less information is available about other possible side effects...
  31. ncbi Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients
    Mark Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 10:301-7. 2005
    ..To study the pharmacokinetics of indinavir/ ritonavir 400/100 mg twice daily in antiretroviral-naive patients at Srinagarind Hospital in Khon Kaen, Thailand...
  32. ncbi Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    J Acquir Immune Defic Syndr 39:523-9. 2005
    ..To assess the safety of 2 intermittent treatment strategies compared with continuous therapy for patients with virologic suppression on highly active antiretroviral therapy (HAART) at baseline...
  33. ncbi Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection
    Richard Tilling
    Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, Royal Free Campus, London NW3 2QG, UK
    AIDS 16:589-96. 2002
    ..To monitor changes in the numbers of CD8 lymphocytes expressing the activated CD38++ phenotype in peripheral blood samples from patients with primary HIV infection (PHI) treated with highly active antiretroviral therapy (HAART)...